Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02348489 · ClinicalTrials.gov registry record · Phase 3
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
A Phase 3 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 815
- Enrollment target
NCT02348489 is a Phase 3 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 815 participants.
The verdict
NCT02348489, a Phase 3 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 815 participants
- Enrollment target
Study Summary
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
Interventions
- DRUG SGI-110 (guadecitabine)
- DRUG Treatment Choice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 815 participants |
| Start Date | 2015-03-19 |
| Est. Completion | 2019-06-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02348489
The ClinicalTrials.gov registry entry for NCT02348489 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 815 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SGI-110 (guadecitabine) is the first listed.
NCT02348489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02348489 about?
NCT02348489 is a clinical study titled "SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction". To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
What is the current status of trial NCT02348489?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 815 participants. The study started on 2015-03-19. Estimated completion is 2019-06-17.
What interventions are being tested in trial NCT02348489?
The interventions under investigation include: SGI-110 (guadecitabine) (DRUG), Treatment Choice (DRUG).
Who is sponsoring clinical trial NCT02348489?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.